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to understanding implications for lifecycle management. Methods: Secondary 
research was conducted to identify approved indications and official list prices 
from the British National Formulary, the French Assurance Maladie database and 
the German Rote List for ranibizumab (Lucentis, Roche) and aflibercept (Eylea, Bayer) 
from launch to 2015. Indications were reviewed based on the EMA and individual 
countries’ official journals. Annualized treatment costs were calculated based on 
the official list prices and compared across countries and over time. Results: 
Ranibizumab was approved in 2007 for wet age-related macular degeneration 
(AMD). In 2010, 2011 and 2013, the list of indications expanded to include diabetic 
macular edema (DME), retinal vein occlusion and pathologic myopia, respectively. 
Aflibercept, another anti-VEGF treatment, gained EMA license in 2012 for wet AMD 
and for DME in 2014. Among countries, France has seen the biggest ranibizumab 
list price discount, with about 44% reduction between 2007 and 2015. In Germany, 
price of ranibizumab dropped by 15% in 2009 before aflibercept and dexametha-
sone (Ozurdex, Allergan) entered the market, and has since remained stable. Price 
of ranibizumab in the UK has remained stable since launch. Aflibercept launched 
at a 36% to 42% lower annual cost compared to ranibizumab across countries. So 
far prices remain stable. ConClusions: Due to different market characteristics, 
the impact of indication expansion on price varies across the markets in scope. 
Maintaining a high list price is complicated in price regulated countries. List prices 
are not affected by subsequent indications in free pricing markets, where contract-
ing and confidential discounts are usually key for access. To maintain high list prices 
and avoid impact of international price referencing, patient access schemes may 
be potential options, but acceptability varies across countries.
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objeCtives: Glaucoma is associated with elevated pressure in the eye (intraocular 
pressure) that may cause injury to the eye if not treated, and as a result, lead to 
blindness. The aim of this study was to identify the types of drug treatments that 
were used between 2013 and 2014 in Brazil. Methods: Patients were identified 
through the health insurance database of Brazil, from January 2013 to December 
2014. The patients were selected with ICD-H40 and its subcategories and bought 
antiglaucoma drugs in the analyzed period. From the date of the purchase, it’s 
possible to obtain a methodology capable of identifying if a patient has used more 
than a drug for the treatment. It was then possible to find the main associations 
of glaucoma ophthalmic solutions. Results: From a total of 169,741 patients who 
bought some kind of antiglaucoma medication, 53,228 used more than one type 
of eye drop. The molecules analyzed were: Timolol, Dorzolamide, Brimonidine, 
Brinzolamide, Travoprost, Bimatoprost and Latanoprost. Since Timolol was the 
most representative drug of this period on purchases and was present in 36.7 % of 
the total purchases, with or without association with another molecule, it has been 
selected the three most representative associations in the sample under study. It 
has been found that Timolol associated with Dorzolamide corresponded to 22.8 % 
of the procurement, followed by associations between Timolol and Brimonidine 
(21.2 %) and Brinzolamide and Timolol (11.2%). ConClusions: Approximately 40% 
of the patients in supplementary health sample from Brazil make use of more 
than one drug for Glaucoma treatment, this fact confirms the protocol realized 
by Brazil’s Health Ministry, where it is described that the therapeutic class, block 
beta-receptor, is the main class for treat Glaucoma and it is usually combined with 
another antiglaucoma class to reduce the intraocular pressure.
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objeCtives: Diabetic Macular Edema (DME) is a leading cause of vision loss and 
blindness. The aim of the study is the evaluation of the benefits concerning the intro-
duction of an additional alternative technology, Dexamethasone intravitreal implant 
(DEX), in comparison with the present scenario consisting of the repeated adminis-
tration of intravitreal injections of Ranibizumab. They differ for the number of injec-
tions and adverse events (AEs) occurring after each therapeutic cycle. Methods: An 
HTA was conducted within 3 Italian Departments of Ophthalmology, in Lombardy 
Region. Qualitative and quantitative data were collected using specific validated 
questionnaires and self-reported interviews, applying a MCDA approach and con-
sidering 7 dimensions resulting from the EUnetHTA Core Model. Results: At the 36 
month time point of the base-case scenario for market penetration, the introduction 
of DEX could lead to i) significant economic savings to the Regional Health Service 
(-15%), even considering the AEs impacts (14.82% severe AEs for Ranibizumab vs 
27.46% mild and moderate AEs for DEX); ii) an optimization of the operating theatre’s 
time, with fewer minutes spent delivering an entire treatment cycle (-27%); iii) a 
perception of improved staff workflow organization (+209%); iv) a decrease of social 
expenditure, in terms of productivity loss, with both transportation and waiting 
time’s reduced (-69%); v)an improvement on equity aspects, considering in particular 
advantages in caregivers’ quality of life (233%), since new treatment requires fewer 
injections. ConClusions: The Resultssuggest that DEX could be considered an 
advantageous technological alternative to adopt within the DME target population. 
It acquired a higher score than the comparator (0.579 vs 0.472, considering the final 
normalized weight derived from the MCDA approach). Economic, organizational and 
equity savings could be reinvested within the same therapeutic area, i) improving 
patient access and adherence to therapy, ii) treating a wider population, iii) reducing 
waiting lists.
inflammatory bowel diseases, eye diseases, metabolic diseases and psychological 
disorders. objeCtives: The main objective of the study is to design an optimized 
Patient Diagnostic Therapeutic Pathway for the Tuscany Region (Italy) character-
ized by higher quality of care and higher levels of organizational and economic 
efficiency. Methods: Research and analysis of the scientific literature and of the 
clinical guidelines on the main dimensions of psoriasis and patient care. Design 
of ad hoc questionnaire useful to collect data and information regarding both the 
organizational structure of the 13 Centers and the different phases of patients 
pathways. Conduction of semi-structured interviews to the clinicians. Realization 
of 13 flow charts representing the patients pathways, from the pre-diagnosis phase 
to the follow-up phase. Results: The analysis shows similarities between the 
Centers in the phases of treatment and follow-up, principally due to their clinical 
nature. Major organizational differences have been recorded in the pre- diagnosis 
and the diagnosis phases due to dissimilar modalities of enrolment of patients. 
The analysis of the thirteen patients pathways has allowed the identification of 
an unique optimized pathway with improved characteristics for the patient. The 
diffusion of the optimized pathway will favour the adoption of a virtuous cycle of 
dialogue between the professionals and the progressive “homogenization” of some 
phases of the hospital management of the patient with psoriasis. ConClusions: 
The study identifies an optimized pathway - able to engage all the clinicians 
involved in the care of the patient and his/her comorbidities - to be adopted at 
the regional level for a more effective, more integrated and efficient management 
of psoriasis.
PSS70
real-World treatment PatternS oF raniBizumaB amonG PatientS 
WitH retinal diSeaSeS in canada: 5 yearS oF data
Rousseau C, Saad R, Davies B, Zaour N
Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada
objeCtives: To assess the annual frequency of injections of ranibizumab over 
time for the treatment of retinal diseases in Canada. Methods: The Rx Dynamics 
database (IMS Health Canada Inc.) for the Ontario Public Drug Program (OPDP), the 
Régie de l’assurance-maladie du Québec (RAMQ) and the national Private Drug Plan 
(PDP) was used for the period ranging from January 2008 to January 2015 to track 
the mean number of claims per year per patient. Longitudinal and cross-sectional 
analyses were performed. Analyses were also performed by indication (wAMD, DME 
and RVO) when the information was available. The index date was defined as the 
date of the first ranibizumab claim. Patients with no active claim of ranibizumab 
during a specific year were not included in the mean of that year. One claim equals 
one injection. Results: For the longitudinal analyses, where the three cohorts of 
patients were followed for 5 consecutive years, the mean number of injections are 
5.9, 5.5, 5.6, 5.7 and 5.9 for the OPDP cohort (n= 12,944), 5.2, 4.7, 5.5, 5.9 and 5.8 for 
the RAMQ cohort (n= 1,835) and 4.2, 5.1, 5.0, 5.4 and 5.1 for PDP (n= 449) cohort. For 
the cross-sectional analyses, the mean number of injections for the first year of 
treatment are 5.9 for the OPDP (n= 60,105), 5.9 for RAMQ (n= 11,557) and 5.1 for PDP 
(n= 5,292). In addition, similar Resultsare obtained when the mean number of injec-
tions is assessed by retinal conditions. ConClusions: These Resultssuggest that 
Canadian patients treated with ranibizumab receive a mean number of injections 
of 5-6 per year over time. These Resultsalso confirm the uptake of individualized 
treatment regimen, such as treat and extend, by the Canadian physicians. All find-
ings and Conclusionsare those of the author, and are based in part on data licensed 
from IMS Health Canada Inc. (all rights reserved).
PSS71
nationWide trend analySiS oF tarGeted tHeraPieS For treatment oF 
maliGnant neoPlaSmS oF tHe eye in taiWan (2009-2016)
Hsu JC1, Gonzalez-Gonzalez L2, Lu V3, Lu CY2
1National Cheng Kung University, Tainan, Taiwan, 2Harvard Medical School, Boston, MA, USA, 
3Sydney Eye Hospital, Chatswood, Australia
objeCtives: Targeted therapies have been used and reimbursed for treatment of 
eye malignancies by Taiwan National Health Insurance in the past few years. This 
study examined the recent trend in use and costs of antineoplastic agents for treat-
ment of eye malignancies in Taiwan from 2009 to 2012. We also forecasted use and 
costs of targeted therapies up to and including year 2016 based on the current 
patterns. Methods: The monthly claims data for eye malignancy-related anti-
neoplastic agents were retrieved from Taiwan’s National Health Insurance Research 
Database (2009-2012). We calculated the number of prescriptions and costs for each 
class of medications, and analyzed their time trends. In addition, using a time series 
design with ARIMA models, we estimated the market share by prescription volume 
and the proportion of costs for targeted therapies for years 2015 and 2016. Results: 
The market share of targeted therapies grew from 1.56% in 2009 to 9.98% in 2012 
among all antineoplastic agents, and the proportion of costs for targeted therapies 
rose from 15.12% in 2009 to 58.88% in 2012. Especially, the proportion of costs for pro-
tein kinase inhibitors grew from 25.62% to 45.28% among all antineoplastic agents 
between 2010 and 2012. The market share and the proportion of costs for targeted 
therapies were predicted to reach 27.33% and 91.39% by the fourth quarter in 2016 
respectively. ConClusions: This is the first study that examined and forecasted 
the use of targeted therapies for treatment of eye malignancies in Taiwan. Our 
findings indicate that, compared with other classes of drugs, targeted therapies 
are becoming the main treatments for eye malignancy in Taiwan, and due to their 
high costs they are likely to cause great economic burden.
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objeCtives: To analyze the impact of indication expansion and market competition 
on anti-VEGF drug prices in the United Kingdom, France and Germany, with a view 
